How Big Data is Helping Unravel CLL Mysteries.

[bkoffman]

Friends,

Today on the CLL Society website cllsociety.org, we share an interview with another researcher from Ohio State University, Dr. Philip Payne, where we discussed biomedical informatics and Big Data in CLL.

WAIT, WAIT, don't skip this one! I promise you'll find it interesting and you won't fall asleep.

Dr. Payne and I met at the CRC (CLL Research Consortium) Scientific Meeting in San Diego in April 2015. Please take a look here to see the interview and important information about what they are doing with all those extra tubes of blood they take when you visit the clinic.

Getting out our first newsletter was pretty exciting and we are already putting together the next issue scheduled to be sent out by the end of the year.

Also, if you have questions you like addressed in future newsletters, OR would be willing to answer 5 questions in our Reader Poll about the CLL Society website, OR would be interested in writing an article for future newsletters, please go to the Ask & Tell section. Our goal is to fulfill the unmet needs of the CLL community, so we always welcome your feedback and questions.

We will be posting a backlog of great lectures and interviews and articles on CLL over the next few months leading up to ASH and signing up for our alert is your best friend in knowing what new material we have posted. Please sign up if you haven’t already.

Save the date: We are planning a post-ASH patient education forum and CLL Society LA support group launch in conjunction with City of Hope and LLS on Dec. 12, 2015. More details to follow.

Stay strong.

We are all this together

Brian Koffman

Volunteer Medical Director of the CLL Society

cllsociety.org

bkoffman.blogspot.com

[AussieNeil Partner Administrator]

Here's an example of how this collected 'Big Data' can be analysed to identify improved personal treatment:

goparallel.sourceforge.net/...

"Cancer genomic research has identified mutations in individual patients and tumors in the past, but using that knowledge to develop improved cancer treatments has been thwarted by researchers’ inability to link the gene mutations to corresponding proteins, which are the targets of most pharmaceutical drugs, according to a recent news release by the University of Copenhagen.

The report notes that University of Copenhagen researchers, along with counterparts at Yale, Zurich, Rome and Tottori, have developed software that computationally translates the effects of cancer mutations on the function of proteins in individual patients. This can unravel how disease mutations target and damage the protein-signaling network inside human cells."

:

:

The researchers recently published their findings in two studies in the journal CELL. Dr. Pau Creixell of BRIC said the new software they developed helps reveal how single DNA mutations can cause “dramatic molecular effects in cells by affecting critical enzymes called kinases.” (My emphasis).

Ibrutinib inhibits Bruton tyrosine kinase, and Idelalisib inhibits phosphoinositide 3-kinase δ; these kinase enzymes are critical to B Cell Receptor signalling in CLL cells.

Drs. Susan O'Brien and Jan Burger from MD Anderson explain more about these kinase inhibitors in this 2014 article:

www2.mdanderson.org/depts/o...

Neil

[jangreen]

Hi this has got to be smart medicine. Making computers work for us. Getting computers to do what they are good at. Best wishes